<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02574650</url>
  </required_header>
  <id_info>
    <org_study_id>CLPR-010</org_study_id>
    <nct_id>NCT02574650</nct_id>
  </id_info>
  <brief_title>Early Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) Also Known as TriAlign™.</brief_title>
  <acronym>SCOUT</acronym>
  <official_title>Early Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) for Symptomatic Chronic Functional Tricuspid Regurgitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitralign, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitralign, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the early safety and performance of the Mitralign
      Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) for the treatment of symptomatic
      chronic functional tricuspid regurgitation (FTR).

      The procedure will be performed with the PTVAS device using a non-surgical percutaneous
      approach to tricuspid valve repair in patients who have FTR with a minimum of moderate
      tricuspid regurgitation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, single-arm, multi-center study, enrolling symptomatic patients with chronic
      functional tricuspid regurgitation and whom left-sided valve surgery is not planned. The
      study will include up to 30 subjects from up to 6 sites. Follow-up evaluations will be
      conducted through 2-years post implantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Technical success at 30-days</measure>
    <time_frame>30-days</time_frame>
    <description>Technical success is defined as freedom from death with: successful access, delivery and retrieval of the device delivery system, and deployment and correct positioning of the intended device(s), and no need for additional unplanned or emergency surgery or re-intervention related to the device or access procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary safety and performance endpoints mid-term and long-term</measure>
    <time_frame>24-months with endpoints measured at dishcarge, 1, 3, 6, 12 and 24 months</time_frame>
    <description>The secondary objectives of the study are to evaluate the acute, mid-term and long-term safety of the device and effects of the device on performance, functional and quality of life parameters, as well as technical, procedural and individual patient successes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a change in Minnesota Living with Heart Failure (MLWHF) Questionnaire and 6-minute walk test (6MWT) as compared to pre-treatment questionnaire responses and pre-treatment total distance walked</measure>
    <time_frame>24-months with endpoints measured at dishcarge, 1, 3, 6, 12 and 24 months</time_frame>
    <description>Participants will complete a MLWHF questionnaire and 6MWT before treatment and at each post treatment follow-up check. Percent change over baseline will be calculated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Symptomatic Functional Tricuspid Regurgitation</condition>
  <condition>Tricuspid Valve Insufficiency</condition>
  <condition>Heart Valve Disease</condition>
  <arm_group>
    <arm_group_label>Open Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-randomized, open label clinical study that intends to treat up to 30 subjects with the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) using standard of care techniques and services that are typically used for structural heart procedures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)</intervention_name>
    <description>Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) delivered by a percutaneous transcatheter procedure.</description>
    <arm_group_label>Open Label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic functional tricuspid regurgitation (FTR) with a minimum of moderate tricuspid
             regurgitation;

          -  ≥18 and ≤85 years old;

          -  NYHA II - IV;

          -  Symptomatic despite Guideline Directed medical Therapy (GDMT), at minimum, patient on
             diuretic use;

          -  LVEF ≥35%

          -  Tricuspid valve annular diameter ≥ 40 mm (or 21 mm/m2 (Superscript)) and ≤55 mm (or 29
             mm/m2 (Superscript))

        Exclusion Criteria:

          -  Pregnant or lactating female;

          -  Severe uncontrolled hypertension (SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg);

          -  Previous tricuspid valve repair or replacement;

          -  Severe coronary artery disease;

          -  MI or known unstable angina within the 30-days prior to the index procedure;

          -  Any PCI within 30 days prior to the index procedure or planned 3 months post the index
             procedure;

          -  Chronic oral steroid use (≥6 months);

          -  Life expectancy of less than 12-months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca Hahn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia Unviersity Medical Center / New York-Presbyterian Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Meduri, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Piedmont Healthcare</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gisella Blanchette</last_name>
    <phone>978-863-2435</phone>
    <email>gblanchette@mitralign.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara Vidmar</last_name>
    <phone>651-338-2475</phone>
    <email>svidmar@mitralign.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saibal Kar, MD</last_name>
      <phone>310-423-3977</phone>
      <email>saibal.kar2@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Saibal Kar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Casias, RN, CCRC</last_name>
      <phone>415-833-3480</phone>
      <email>Cristina.Casias@kp.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Rassi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lowell Satler, MD</last_name>
      <phone>202-877-5975</phone>
      <email>satlerlowell@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Lowell Satler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delray Medical Center</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33484</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Hudson</last_name>
      <phone>561-495-3145</phone>
      <email>Laura.Hudson@tenethealth.com</email>
    </contact>
    <investigator>
      <last_name>Brijeshwar Maini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Meduri, MD</last_name>
      <phone>404-605-6517</phone>
      <email>christopher.meduri@piedmont.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Meduri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University / Bluhm Cardiovascular Institute</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart Rich, MD</last_name>
      <phone>312-695-9979</phone>
      <email>srich@nm.org</email>
    </contact>
    <investigator>
      <last_name>Stuart Rich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Meyer</last_name>
      <email>Karen.Meyer2@allina.com</email>
    </contact>
    <investigator>
      <last_name>Mario Goessl, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center / New York-Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Hahn, MD</last_name>
      <phone>212-305-7060</phone>
      <email>rth2@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Rebecca Hahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Green</last_name>
      <email>LMGreen@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Colin Baker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Lim, MD</last_name>
      <phone>434-982-1058</phone>
      <email>sl9pc@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Lim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Drouhard</last_name>
      <email>Andrea.Drouhard@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Sameer Gafoor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2015</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

